Evidence map›Paper›PMID 24843469›Full record

ArticleJournal of diabetes investigation2011

GLP-1 receptor agonist attenuates endoplasmic reticulum stress-mediated β-cell damage in Akita mice.

Shunsuke Yamane, Yoshiyuki Hamamoto, Shin-Ichi Harashima, Norio Harada, Akihiro Hamasaki, Kentaro Toyoda, Kazuyo Fujita, Erina Joo, Yutaka Seino, Nobuya Inagaki

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Journal of diabetes investigation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02882477 (Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based Therapy), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02882477 phase2 / phase3unknown statusstarted 2016, after this paper: background citation

Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based Therapy

Ran2016Enrolled20Registered outcomes6Posted comparisons0ConditionsDiabetes Mellitus, Gastroduodenal Ulcer, Iron Metabolism Disorders, Optic AtrophyArmsacetylcysteine, Deferiprone, Sitagliptin and Metformin
Open the trial in the graph
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Shunsuke YamaneDepartment of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University.
Yoshiyuki HamamotoCenter for Diabetes and Endocrinology, Tazuke Kofukai Medical Research Institute, Kitano Hospital.
Shin-Ichi HarashimaDepartment of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University.
Norio HaradaDepartment of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University.
Akihiro HamasakiDepartment of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University.
Kentaro ToyodaDepartment of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University.
Kazuyo FujitaDepartment of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University.
Erina JooDepartment of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University.
Yutaka SeinoDivision of Diabetes, Clinical Nutrition and Endocrinology, Department of Medicine, Kansai Electric Power Hospital, Osaka, Japan.
Nobuya InagakiDepartment of Diabetes and Clinical Nutrition, Graduate School of Medicine, Kyoto University ; CREST of Japan Science and Technology (JST), Kyoto.
Kyoto University · JPKansai Electric Power Hospital · JPKitano Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledAims/Introduction:  Endoplasmic reticulum (ER) stress is one of the contributing factors in the development of type 2 diabetes. To investigate the cytoprotective effect of glucagon-like peptide 1 receptor (GLP-1R) signaling in vivo, we examined the action of exendin-4 (Ex-4), a potent GLP-1R agonist, on β-cell apoptosis in Akita mice, an animal model of ER stress-mediated diabetes. MATERIALS AND

methodsEx-4, phosphate-buffered saline (PBS) or phlorizin were injected intraperitoneally twice a day from 3 to 5 weeks-of-age. We evaluated the changes in blood glucose levels, bodyweights, and pancreatic insulin-positive area and number of islets. The effect of Ex-4 on the numbers of C/EBP-homologous protein (CHOP)-, TdT-mediated dUTP-biotin nick-end labeling (TUNEL)- or proliferating cell nuclear antigen-positive β-cells were also evaluated.

resultsEx-4 significantly reduced blood glucose levels and increased both the insulin-positive area and the number of islets compared with PBS-treated mice. In contrast, there was no significant difference in the insulin-positive area between PBS-treated mice and phlorizin-treated mice, in which blood glucose levels were controlled similarly to those in Ex-4-treated mice. Furthermore, treatment of Akita mice with Ex-4 resulted in a significant decrease in the number of CHOP-positive β-cells and TUNEL-positive β-cells, and in CHOP mRNA levels in β-cells, but there was no significant difference between the PBS-treated group and the phlorizin-treated group. Proliferating cell nuclear antigen staining showed no significant difference among the three groups in proliferation of β-cells.

conclusionsThese data suggest that Ex-4 treatment can attenuate ER stress-mediated β-cell damage, mainly through a reduction of apoptotic cell death that is independent of lowered blood glucose levels. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2010.00075.x, 2010).

Indexed as

ApoptosisEndoplasmic reticulum stressGlucagon‐like peptide‐1

Identifiers

PMID24843469
PMCPMC4015545
OpenAlexW1613429158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.